[vc_row][vc_column][vc_column_text css=""]MELBOURNE, AUSTRALIA & EDEN PRAIRIE, MN, 16 June 2026 Annual Awards Honor Breakthrough Innovations Driving Meaningful Global Impact. Atmo Biosciences is proud to announce that it has been named a winner of Fast Company’s 2026 World Changing Ideas Awards. This annual recognition honors bold and transformative efforts that tackle the world’s most pressing issues—from sustainability initiatives and AI developments to cutting-edge medical devices at the forefront of their field. Now in its ninth year, the World Changing Ideas Awards celebrate organizations and projects that are delivering measurable impact across industries. Atmo’s FDA-cleared ingestible capsule fits the Awards criteria by using novel, gas-sensing...

[vc_row][vc_column][vc_column_text css=""]MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 26 May 2026 Atmo Biosciences, a leader in ingestible capsule technology, announced that it has received US Food and Drug Administration (FDA) 510(k) clearance for a new Contractility Frequency Map feature as an enhancement to the existing Atmo Gas Capsule System.   This clinically valuable feature is a visualisation of gastrointestinal contractions based on measurements of the Capsule movement caused by gastrointestinal pressures and contractions. The addition of this feature enables clinicians to see the different rates and intensities of contractile activity in the stomach, small bowel, and colon. These mechanical data provide insights into physiology...

MELBOURNE AND SYDNEY AUSTRALIA, 15 September 2022: Atmo Biosciences, a clinical stage gut health company, is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule. The Atmo Gas Capsule is the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function. The granted patent protects the ingestible capsule’s unique gas-sensing functionality and the ability to wirelessly transmit the data it collects. Atmo has an exclusive, worldwide license for the patent from RMIT University – where the original technology was invented. Malcolm Hebblewhite, Atmo CEO and Managing Director commented: “The...

MELBOURNE AND SYDNEY AUSTRALIA, 5 October 2022: Atmo Biosciences, a clinical stage gut health company developing the World’s first ingestible gas-sensing capsule, is pleased to announce publication of a clinical study supporting the Atmo Gas Capsule’s ability to determine its location in the gastrointestinal tract. The study demonstrates strong agreement between data from Atmo’s Gas Capsule and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects. Based on these encouraging data, Atmo intends to conduct a clinical trial in patients with gastrointestinal motility disorders. The paper, entitled “Comparison of gastrointestinal landmarks using the gas-sensing capsule and wireless...

MELBOURNE AND SYDNEY AUSTRALIA, 5 May 2022: Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels:Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists. Kate Hill has been appointed to the Atmo Biosciences Board as a Non-Executive Director. Dr Carl Runde joins Atmo as Chief Financial Officer, and Sue Dafnias has been appointed as Head...

MELBOURNE AND SYDNEY AUSTRALIA, 26 July 2022: Atmo Biosciences, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gastrointestinal health and microbiome function, has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists. The Atmo MAB met for the first time recently in conjunction with the Digestive Disease Week conference, held in San Diego. The MAB will provide valuable insight into opportunities for the company to address unmet clinical needs in gastroenterology and expand the clinical utility of the unique Atmo technology platform. The MAB is also contributing crucial clinical input to the design of Atmo’s upcoming pivotal...

• Capital raise led by existing shareholder Otsuka Pharmaceutical, a leading Japanese pharmaceutical company • New capital provides funds to undertake a pivotal study to support an application for regulatory clearance in a first indication for Atmo’s unique, ingestible gas-sensing capsule to assess gastrointestinal motility • Atmo also progressing pilot study for small intestinal bacterial overgrowth (SIBO), a common and debilitating gut disorder. MELBOURNE AND SYDNEY AUSTRALIA, 30 March 2023: Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, has raised A$8 million in a fully subscribed Series B funding round. The raise was...

• 85 patients recruited in multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders. MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 4 October 2023: Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders. More than 85 patients from 10 different trial sites in the U.S. and Australia have now...